William Blair analyst Matt Larew has maintained their bullish stance on RGEN stock, giving a Buy rating on March 5.
Matt Larew has given his Buy rating due to a combination of factors related to Repligen’s strategic acquisition of 908 Devices’ bioprocessing desktop assets. This acquisition is expected to enhance Repligen’s product offerings and strengthen its position in the bioprocessing market, which is a key growth area for the company.
Furthermore, the integration of these assets is anticipated to drive operational efficiencies and expand Repligen’s customer base, ultimately contributing to increased revenue potential. Larew’s analysis suggests that these strategic moves will likely result in significant long-term value for shareholders, justifying the Buy rating.
According to TipRanks, Larew is an analyst with an average return of -8.6% and a 47.06% success rate. Larew covers the Healthcare sector, focusing on stocks such as Repligen, Amedisys, and Maravai Lifesciences Holdings.
In another report released on March 5, TD Cowen also maintained a Buy rating on the stock with a $200.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com